Table 1 Demographics, diagnoses and characterization of angioedema
From: Review of icatibant use in the Winnipeg Regional Health Authority
Category | n | Stratification | Count (% of n) | p-value (*< 0.05) |
|---|---|---|---|---|
Presentations with icatibant dispensation | 23 | NA | 23 (100) | NA |
Diagnosis | 23 | HAE nC1INH | 10 (43) 10 (43) | |
ACEIIAE | 11 (48) | |||
Not yet diagnosed | 1 (4) | |||
tPA-induced angioedema | 1 (4) | |||
Sex | 23 | Any diagnosis | ||
Male | 8 (35) | 0.11 | ||
Female | 15 (65) | |||
10 | HAE | |||
Male | 3 (30) | 0.95 | ||
Female | 7 (70) | |||
13 | Non-HAE | |||
Male | 5 (38) | 0.87 | ||
Female | 8 (62) | |||
Age | 23 | All—median years (range) | 57.5 (35–82) | NA |
10 | HAE—median years (range) | 52 (35–60) | 0.02* | |
13 | Non-HAE—median years (range) | 73.5 (37–82) | ||
Localization of angioedema | 23 | Any diagnosis | NA | |
Face/oropharolarynx | 16 (70) | |||
Abdominal | 9 (39) | |||
Cutaneous | 6 (26) | |||
10 | HAE | |||
Face/oropharolarynx | 4 (40) | |||
Abdominal | 8 (80) | |||
Cutaneous | 1 (10) | |||
13 | Non-HAE | |||
Face/oropharolarynx | 12 (92) | |||
Abdominal | 1 (8) | |||
Cutaneous | 5 (38) | |||
History of allergy | 6 | HAE | 1 (17) | |
Non-HAE | 5 (83) | |||
ACEI prescribed | 11 | Fosinopril | 2 (18) | |
Lisinopril | 3 (27) | |||
Perindopril | 3 (30) | |||
Quinapril | 1 (10) | |||
Ramipril | 2 (20) | |||